How does tigecycline's liver enzyme impact change over long term use?

Short answer:
- Tigecycline can cause changes in liver enzymes (ALT/AST, and sometimes alkaline phosphatase or bilirubin). These changes are relatively uncommon, but they can occur, and more so with longer or repeated courses.
- The drug is not heavily metabolized by the liver and, in mild to moderate hepatic impairment, no dose adjustment is usually needed. Data for severe hepatic impairment are limited.
- If long-term or extended therapy is used, liver function should be monitored, and any signs of liver injury should prompt reconsideration of therapy.

What this means in practice:
- Monitoring: baseline liver tests (ALT, AST, ALP, total bilirubin) before starting tigecycline, then periodic monitoring during prolonged use.
- Interpreting changes: small, transient increases in liver enzymes can occur. Consider holding or adjusting therapy if:
- ALT/AST rise >3 times the upper limit of normal (ULN) with symptoms, or
- ALT/AST rise >5 times ULN even without symptoms, or
- bilirubin rises or there are signs of liver injury (jaundice, dark urine, fatigue, right upper-quadrant pain).
- Long-term use: because prolonged therapy may carry higher risk, clinicians typically limit duration to the shortest effective course and weigh benefits vs. potential hepatotoxicity.

If you have a specific patient context (liver disease history, dose/duration, concurrent meds), I can tailor guidance more precisely. And as always, this information is general—final decisions should come from a clinician.